Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

Table 1 Efficacy (% resolution of incontinence) and discontinuation data included into the economic model

% Resolution of incontinence (<1 episode/24 hrs)	W2	W8	W12	W12\|W8	W12\|~W8
Placebo	20,99%	34,66%	27,84%	80,33%	14,16%
Fesoterodine 4 mg	30,41%	50,00%	43,67%	87,34%	21,05%
Fesoterodine 8 mg	40,59%^a	55,38%^a	50,21%	90,65%	24,20%
Tolterodine	29,23%	49,47%	38,18%	77,17%	13,04%
Solifenacin 5 mg^c	31,49%	51,99%	41,76%	80,33%^d	21,24%
Solifenacin 10 mg^e	32,11%^a	53,01%^a	42,58%	80,33%^d	21,66%^b
Other data	% Nocturia *(> = 2 episodes/night)* % of patients with nocturia at baseline without nocturia at W12			Constipation
Placebo	54,34%			1,99%
Fesoterodine 4 mg	55,56%			4,15%
Fesoterodine 8 mg	55,90%			6,01%
Tolterodine	57,69%			2,76%
Solifenacin 5 mg	54,34%ⁱ			3,53%^j
Solifenacin 10 mg	88,72%^j			7,72%^j
Discontinuation	W2		W8	W12	W24 ^f	W52 ^f
Placebo	100%		92,84%	90,64%	79,32%	59,27%
Fesoterodine 4 mg	100%		92,67%^g	equal to placebo data ^h
Fesoterodine 8 mg	--		--	equal to placebo data ^h
Tolterodine	100%		95,76%	equal to placebo data ^h
Solifenacin 5 mg	100%		94,06%	equal to placebo data ^h
Solifenacin 10 mg	--		--	equal to placebo data ^h

The symbol "|" denotes conditional response rates; the response at week 12 given response at week 8. The symbol "~" denotes non-response; no-response at week 12 given no-response at week 8
Source: Fesoterodine phase III trials, except when a different source is described [17, 18].
a - values not used in the decision tree; only used to calculate conditional response rates
b - conditional response rates estimated by applying the W8 low dose: high dose response ratio to the W12|~W2(~W8) non-titrating response rate
c - equal to 1,5 times the placebo rates [29]
d - conditional response equal to placebo rate
e - equal to 1,5294 times the placebo rates [29]
f - W24 and W52 values were extrapolated from clinical trial data using an exponential decay curve fitted to W2, W8, and W12 discontinuation values
g - discontinuation rate of fesoterodine 4 mg at W8 in the trial data was greater than that of placebo at W12, therefore this value was set equal to the W12 rate.
h - discontinuation rates at week 12 were found to be not statistically significant for any treatment [30], therefore the values are equal to placebo discontinuation
i - relative rates from published literature [42]; solifenacin 5 mg not found to be significantly different than placebo; solifenacin 10 mg 63.28% higher than placebo
j - relative rates from published literature [29]; solifenacin 5 mg 1,778 times placebo; solifenacin 10 mg 3,889 times higher than placebo

ISSN: 1471-2490